We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.08 | -0.19% | 42.49 | 9,508 | 10:53:26 |
From May 2019 to May 2024
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) said Friday that headline results from its DREAMM-2 study for treatment of multiple myeloma, a type of blood cancer, were positive.
The pharmaceutical company said the two-arm study of its treatment belantamab mafodotin met its primary objective and demonstrated a clinically meaningful overall response rate.
Safety and tolerability was consistent with that observed in the DREAMM-1 study, GlaxoSmithKline said.
Data from the DREAMM-2 study will be the basis for regulatory filings starting later this year, the company said. Belantamab mafodotin is on track for regulatory submission by the end of 2019, it said.
Write to Oliver Griffin at oliver.griffin@dowjones.com; @OliGGriffin
(END) Dow Jones Newswires
August 23, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
